Cheng CY, Hao WR, Cheng TH. Enhancing the outcomes of diabetic vitrectomy with pharmacological adjuvants. World J Methodol 2025; 15(2): 98912 [DOI: 10.5662/wjm.v15.i2.98912]
Corresponding Author of This Article
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404328, Taiwan. thcheng@mail.cmu.edu.tw
Research Domain of This Article
Ophthalmology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Methodol. Jun 20, 2025; 15(2): 98912 Published online Jun 20, 2025. doi: 10.5662/wjm.v15.i2.98912
Enhancing the outcomes of diabetic vitrectomy with pharmacological adjuvants
Chun-Yao Cheng, Wen-Rui Hao, Tzu-Hurng Cheng
Chun-Yao Cheng, Department of Ophthalmology, Cathay General Hospital, Taipei 10633, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404328, Taiwan
Co-corresponding authors: Wen-Rui Hao and Tzu-Hurng Cheng.
Author contributions: Cheng CY and Hao WR contributed equally to this editorial, with both authors collaboratively drafting the initial content and structuring the editorial’s key messages. Hao WR and Cheng TH provided critical oversight during the revision process, ensuring the editorial accurately reflected recent advances in the field and maintained high scientific integrity. Cheng CY, Hao WR, and Cheng TH were actively involved in refining the content and enhancing the clarity of the argument. All authors read and approved the final manuscript. As co-corresponding authors, Hao WR and Cheng TH equally contributed to the editorial’s conceptual direction, revision process, and approval, ensuring the editorial’s alignment with the latest research and clinical practices.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: July 9, 2024 Revised: October 11, 2024 Accepted: October 23, 2024 Published online: June 20, 2025 Processing time: 141 Days and 4.2 Hours
Abstract
This editorial offers insights from a minireview by Venkatesh et al, who explored pharmacological adjuvants for diabetic vitrectomy. Specifically, they synthesized current knowledge and evaluated the efficacy of various adjunctive therapies in improving the outcomes of diabetic retinopathy and managing associated complications. Herein, we highlight the key roles of pharmacological adjuvants in optimizing surgical techniques, minimizing intraoperative challenges, and enhancing postoperative recovery. We further discuss the potential implications of this approach for clinical practice and future research directions in this evolving field. Overall, this editorial underscores the importance of incorporating pharmacological adjuvants into standard diabetic vitrectomy care to improve surgical outcomes and thus patients’ quality of life.
Core Tip: Incorporating pharmacological adjuvants into diabetic vitrectomy can significantly enhance surgical outcomes and postoperative recovery. These therapies reduce intraoperative complications like bleeding and improve surgical precision while minimizing postoperative issues, including inflammation and fibrosis. Therefore, the incorporation of these adjunctive treatments into routine clinical practice is crucial for improving patient care, lowering complication rates, and enhancing long-term visual outcomes for those undergoing diabetic vitrectomy.
